<code id='CF9DDDC805'></code><style id='CF9DDDC805'></style>
    • <acronym id='CF9DDDC805'></acronym>
      <center id='CF9DDDC805'><center id='CF9DDDC805'><tfoot id='CF9DDDC805'></tfoot></center><abbr id='CF9DDDC805'><dir id='CF9DDDC805'><tfoot id='CF9DDDC805'></tfoot><noframes id='CF9DDDC805'>

    • <optgroup id='CF9DDDC805'><strike id='CF9DDDC805'><sup id='CF9DDDC805'></sup></strike><code id='CF9DDDC805'></code></optgroup>
        1. <b id='CF9DDDC805'><label id='CF9DDDC805'><select id='CF9DDDC805'><dt id='CF9DDDC805'><span id='CF9DDDC805'></span></dt></select></label></b><u id='CF9DDDC805'></u>
          <i id='CF9DDDC805'><strike id='CF9DDDC805'><tt id='CF9DDDC805'><pre id='CF9DDDC805'></pre></tt></strike></i>

          
          WSS

          Which presentations are worth catching at ASCO this weekend? What is exon-skipping? And how do you pronounce bronchiectasis?

          This week on “The Readout LOUD,” we preview some of the research that will be presented at the American Society of Clinical Oncology conference in Chicago. We also discuss the latest news in the health and life sciences, including a milestone in lung disease R&D and a Duchenne muscular dystrophy confirmatory trial failure.  

          advertisement

          To read more about Merus’ combination therapy, go here; For more on Johnson & Johnson’s mixed data, click here; For more on Nippon Shinyaku’s Duchenne drug trial failure, go here; To read more on Insmed’s bronchiectasis treatment, click here; To sign up for STAT’s ASCO newsletter, click here.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          Leave your comment

          Please enter your name
          Please enter your comment

          hotspot